To view this email as a web page, click here .

Please join us to learn about an FDA-approved first-line monotherapy option in advanced NSCLC

Thursday, December 9, 2021 • 7:00 PM ET

Topics of discussion at this event include:

Historical clinical trial eligibility considerations in advanced NSCLC Clinical evidence, safety profile, and post-hoc and exploratory analyses from one of the largest advanced NSCLC clinical trials conducted to date Resources to help support your eligible patients

Expert insights provided by:

Edgardo Santos, MD Founding Partner- Florida Precision Oncology, Hematology/Oncology Specialist  Aventura, FL

In accordance with the PhRMA Code on Interactions with Healthcare Professional, this Program is limited to U.S. Healthcare Professionals and persons with bona fide professional interest in the information presented. No CME credits offered for attendance of this program.

Sponsored by

ONC.21.08.0034 9/21

This email was sent by: %%Member_Busname%% %%Member_Addr%%, %%Member_City%%, %%Member_State%%, %%Member_PostalCode%% %%Member_Country%% Privacy Policy Update Profile        Manage Subscriptions        Unsubscribe